Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

efocipegtrutide

A long-acting glucagon/gastric inhibitory peptide (GIP)/glucagon-like peptide-1 (GLP-1) triple receptor agonist conjugated with constant region of human immunoglobulin via a non-peptidyl flexible linker, with potential antihyperglycemic, anti-inflammatory and anti-fibrotic activities. Upon administration, efocipegtrutide binds to and activates multiple incretin receptors, including glucagon receptor (GCGR), GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), which may decrease liver fat accumulation, inflammation and fibrogenesis, and normalize blood glucose levels.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	HM 15211 HM-15211 HM15211

efocipegtrutide

Search NCI's Drug Dictionary